Form 8-K - Current report:
SEC Accession No. 0001213900-25-052413
Filing Date
2025-06-09
Accepted
2025-06-09 10:38:59
Documents
12
Period of Report
2025-06-09
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0245071-8k_unicycive.htm   iXBRL 8-K 34553
  Complete submission text file 0001213900-25-052413.txt   202659

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE uncy-20250609.xsd EX-101.SCH 3017
3 XBRL LABEL FILE uncy-20250609_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE uncy-20250609_pre.xml EX-101.PRE 22360
14 EXTRACTED XBRL INSTANCE DOCUMENT ea0245071-8k_unicycive_htm.xml XML 3787
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

EIN.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40582 | Film No.: 251033083
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)